A substantial number of clinical trials using antiangiogenic therapies are ongoing worldwide.
How to achieve the maximum benefit from these therapies and how to monitor patient …

Through the recent conduct of the ToGA trial, HER2 has shown to be predictive for the
treatment with trastuzumab in advanced gastric and gastro-oesophageal cancer. When it …

Aims: Human epidermal growth factor receptor 2 (HER2) overexpression/amplification is
implicated in the development of various solid tumour types. Validated methods and scoring …

The mammalian forkhead box (Fox) transcription factor FoxM1b is implicated in
tumorigenesis. However, the presence of expression and role of FoxM1b in gastric cancer …

Amplification of the HER2 gene and over-expression of the HER2 protein in gastric cancer
have been shown in a large number of studies. HER2 positivity can be detected in …

Gastric cancer is one of the leading causes of cancer death worldwide. Because of its
heterogeneity, gastric cancer has been an interesting model for studying carcinogenesis …

Gastric cancer (GC) is a major public health issue as the fourth most common cancer and
the second leading cause of cancer-related death. Recent advances have improved our …

Background: Epidermal growth factor receptor (EGFR or HER1) and its homolog c-erbB-2
(HER2) are membrane receptors. Both EGFR and HER2 genes are overexpressed in a …

Background In gastric cancer, the recurrence rate is high even after curative surgery. A
relevant issue is the identification of independent prognostic factors to select high‐risk …

Purpose: Angiogenic behavior is a critical aspect of cancer biology and subject to regulation
by multiple molecular pathways. Because the signal transducer and activator of transcription …